The opportunity to service such a vast patient population [in India] is huge and we made this our main mission
In Conversation
Interview: Janis Silins – Managing Member of the Board, Association of Biopharmaceutical Drug Manufacturers in Latvia (BRAL)

"We strive to play a proactive role in fostering the emergence of a financially sustainable and high-performance healthcare system in which patients gain ready access to…
Interview: Roberto Aspiazu – Executive Director, Ecuadorian Business Committee (CEE); President, Mexican Chamber of Commerce in Ecuador

"Unlike other neighboring countries on the Latin American continent, Ecuador’s dollarized economy protects all type of investments from the risk of inflation, which are common in…
"The single most important feature of Mint Pharmaceuticals is our mission, which is to be a leading supplier of high quality and affordable generics."
"The Lithuanian primary healthcare system has been recognized as an example of good practices and many countries are interested in implementing the same system in their…
"Poland does not reimburse innovative drugs to a large extent, and this is a dominant reason why it is important to explain thoroughly the peculiarities of…
"We at MSD believe that the government may consider recognizing the need to invest more in innovative medicines."
"In our region, we follow the global footprint quite closely with reproductive medicine and women’s health as our strongest therapy areas, followed by gastroenterology and urology."
"Our flexibility and capacity to adapt on a project basis really is our strength. as, we do not have the bureaucracy of a large CRO."
Interview: Leonardo Maffioli – Senior Marketing and Commercial Manager Fertility and Endocrinology, IBSA

"Within human reproduction, our Polish sales and marketing team is in close contact with all IVF clinicians and gynaecologists, and there are plans to conduct local…
"Our priority as a company is to forge more partnerships with companies that want to take advantage of the richness of the world's ninth biggest pharmaceutical…
Access to medication is at the company’s core; what we do is ensure scale gain so that we can have competitive costs and prices